Cargando…

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

Detalles Bibliográficos
Autores principales:	Hemming, Matthew L., Nathenson, Michael J., Lin, Jia-Ren, Mei, Shaolin, Du, Ziming, Malik, Karan, Marino-Enriquez, Adrian, Jagannathan, Jyothi P., Sorger, Peter K., Bertagnolli, Monica, Sicinska, Ewa, Demetri, George D., Santagata, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055910/ https://www.ncbi.nlm.nih.gov/pubmed/32133433 http://dx.doi.org/10.1200/PO.19.00287

Ejemplares similares

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022)

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report
por: Pircher, Magdalena, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
por: Percy, Catherine, et al.
Publicado: (2021)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion
por: Thorwarth, Anne, et al.
Publicado: (2022)

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
por: Palmerini, Emanuela, et al.
Publicado: (2023)

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
por: Wells, A.E., et al.
Publicado: (2019)

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
por: Zhang, Lei, et al.
Publicado: (2021)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
por: Torre, Matthew, et al.
Publicado: (2020)

Larotrectinib for solid tumours
Publicado: (2022)

NTRK3 Overexpression in Undifferentiated Sarcomas with YWHAE and BCOR Genetic Alterations
por: Kao, Yu-Chien, et al.
Publicado: (2020)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
por: Zhou, Ning, et al.
Publicado: (2018)

Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report
por: Huang, Wen-Kuan, et al.
Publicado: (2023)

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer
por: Vaishnavi, A., et al.
Publicado: (2013)

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
por: Bielack, S S, et al.
Publicado: (2019)

Oncogenic role of a developmentally regulated NTRK2 splice variant
por: Pattwell, Siobhan S., et al.
Publicado: (2022)

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion
por: Song, Zhengbo, et al.
Publicado: (2021)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020)

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
por: Flavahan, William A, et al.
Publicado: (2019)

Refractory and metastatic infantile fibrosarcoma harboring LMNA–NTRK1 fusion shows complete and durable response to crizotinib
por: Bender, Jonathan, et al.
Publicado: (2019)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
por: Rosen, Ezra Y., et al.
Publicado: (2019)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
por: Waguespack, Steven G, et al.
Publicado: (2022)

Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases
por: Lapeña, Lucas Moratilla, et al.
Publicado: (2022)

Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib
por: Sahni, Shubham, et al.
Publicado: (2023)

The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations
por: Kinnunen, Matias, et al.
Publicado: (2023)

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
por: DuBois, Steven G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ma7avfpfum85dv66joqo29m8bu